Is VIVS or VKTX more undervalued in 2026?

CirclFi compares VivoSim Labs, Inc. (VIVS) and Viking Therapeutics, Inc. (VKTX) using 13 institutional-grade valuation models. VIVS has a Quality of Company score of 4.5/10 while VKTX scores 4.7/10.

Which is a better buy — VIVS or VKTX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do VIVS and VKTX valuations compare?

VIVS at $1.31 and VKTX at $32.19 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

VIVS vs VKTX Valuation Comparison 2026 — Intrinsic Value Analysis

VIVS

Biotechnology

VivoSim Labs, Inc.

Quality

4.5

out of 10

Value Trap

LOW

Price

$1.31

Last close

Models

10/13

Active

VKTX

Biotechnology

Viking Therapeutics, Inc.

Quality

4.7

out of 10

Value Trap

SAFE

Price

$32.19

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	VIVS Fair Value	VIVS Upside	VKTX Fair Value	VKTX Upside
Bayesian DCF	Intrinsic	$1.03	-21.2%	$10.25	-68.1%
Earnings Power Value	Intrinsic	$3.09	+114.7%	$14.75	-55.0%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for VIVS vs VKTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

VIVS vs VKTX — Which Stock Is More Undervalued?

VKTX scores higher with a 4.7/10 quality rating vs VIVS's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing VivoSim Labs, Inc. (VIVS) and Viking Therapeutics, Inc. (VKTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

VIVS currently trades at $1.31 with a QOC of 4.5/10, while VKTX trades at $32.19 with a QOC of 4.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).